Autoantigen Golgin-97, an Effector of Arl1 GTPase, Participates in Traffic from the Endosome to the Trans-Golgi Network

Lei Lu,* Guihua Tai,* and Wanjin Hong†

Membrane Biology Laboratory, Institute of Molecular and Cell Biology, Singapore 138673, Singapore

Submitted December 5, 2003; Revised June 20, 2004; Accepted July 8, 2004

Monitoring Editor: Vivek Malhotra

The precise cellular function of Arl1 and its effectors, the GRIP domain Golgins, is not resolved, despite our recent understanding that Arl1 regulates the membrane recruitment of these Golgins. In this report, we describe our functional study of Golgin-97. Using a Shiga toxin B fragment (STxB)-based in vitro transport assay, we demonstrated that Golgin-97 plays a role in transport from the endosome to the trans-Golgi network (TGN). The recombinant GRIP domain of Golgin-97 as well as antibodies against Golgin-97 inhibited the transport of STxB in vitro. Membrane-associated Golgin-97, but not its cytosolic pool, was required in the in vitro transport assay. The kinetic characterization of inhibition by anti-Golgin-97 antibody in comparison with anti-Syntaxin 16 antibody established that Golgin-97 acts before Syntaxin 16 in endosome-to-TGN transport. Knock down of Golgin-97 or Arl1 by their respective small interference RNAs (siRNAs) also significantly inhibited the transport of STxB to the Golgi in vivo. In siRNA-treated cells with reduced levels of Arl1, internalized STxB was instead distributed peripherally. Microinjection of Golgin-97 antibody led to the fragmentation of Golgi apparatus and the arrested transport to the Golgi of internalized Cholera toxin B fragment. We suggest that Golgin-97 may function as a tethering molecule in endosome-to-TGN retrograde traffic.

INTRODUCTION

In eukaryotic cells, different types of cargo (solutes, lipids, and membrane proteins, including receptors and their ligands) internalized from the plasma membrane follow several routes upon reaching the early/sorting endosome. They could recycle back to the plasma membrane directly via early/sorting endosome or indirectly via the recycling endosome, or travel further to the lysosome via the late endosome. Recently, there was evidence suggesting the existence of two retrograde transport pathways from endosomes to the trans-Golgi network (TGN) (Ghosh et al., 1998; Mallard et al., 1998; Mallet and Maxfield, 1999). One pathway, used by furin (Mallet and Maxfield, 1999) and mannose-6-phosphate receptor (M6PR) (Diaz and Pfeffer, 1998; Sincock et al., 2003), is from the late endosome to the TGN. The other one, used by TGN38 (Ghosh et al., 1998), Shiga Toxin B fragment (STxB) (Mallard et al., 1998) and likely GLUT4 (Shewan et al., 2003), proceeds via the early endosome (EE) and/or the recycling endosome (RE), without passing through late endosomes. In addition, the large cation-independent M6PR and the small cation-dependent MPR46 are recently shown to also use this EE/RE–TGN pathway, in addition to its well characterized late endosome–TGN route (Medigeshi and Schu, 2003; Lin et al., 2004). These endosome–TGN pathways could be used by other proteins such as P-selectin (Straley and Green, 2000), membrane-type matrix metalloproteinases (Kang et al., 2002; Zucker et al., 2002; Remacle et al., 2003; Wang et al., 2004a,b), copper transporters (Petrus and Mercer, 1999; Petris et al., 2002), and VAMP4, a TGN SNARE (unpublished observations). In addition, endosome–TGN transport was exploited by HIV-1 Nef protein to down-regulate cell surface levels of class I major histocompatibility complex (Piguet et al., 2000; Blagoveshchenskaya et al., 2002; Larsen et al., 2004).

Vesicle-mediated transport involves three major steps. The first step, the biogenesis of a vesicle, involves membrane budding and cargo selection that is executed by the coat proteins, such as COPI, COPII, and AP-1 clathrin coats (Scales et al., 2000; Antonny and Schekman, 2001; Boehm and Bonifacino, 2001). In the second step, the vesicles move along the cytoskeleton and anchor to the membrane of a target compartment by its interacting with tethering molecules (or complexes) (Pfeffer, 1999). Rab small GTPases, and their effectors are reported to regulate both processes (Zerial and McBride, 2001). Finally, the vesicle docking and fusion with the membrane of an acceptor compartment is mediated by SNAREs and Sec1/Munc18 proteins (Chen and Scheller, 2001). Some molecular machineries in EE/RE–TGN transport are being revealed through the use of a sulfation based in vitro transport assay, which monitors the sulfation of recombinant STxB or MPR46 as an indication of trafficking to the TGN (Mallard et al., 2002; Mallard and Johannes, 2003; Medigeshi and Schu, 2003). Similar to biosynthetic/secretory traffic, it had been reported that EE/RE–TGN transport may require AP-1, AP-3, Rab proteins (including Rab 6A and Rab11), Rab effectors (Rab6IP2), and SNAREs, including VAMP3, VAMP4, Syntaxin 6, Syntaxin 16, and Vti1a (Mallard et al., 1998; Wulke et al., 2000; Monier et al., 2002; Medigeshi and Schu, 2003). More players involved in this retrograde transport are expected, and among them, the tethering molecules (or complexes) are still elusive. We
Figure 1. The recombinant GRIP domain of Golgin-97 inhibited in vitro EE/RE–TGN transport. (A) Schematic representation of the GRIP domain and the central coiled-coil region (Golgin-97CC) used in this study. (B) Relative efficiencies of STxB transport to the TGN as measured by the extents of its sulfation under various conditions as indicated. Lanes 1 and 4 are positive controls, and the transports were set as 100%. In lane 2, the assay contains 133 μg/ml GST-GRIP. In lane 3, GST-GRIP (133 μg/ml) was preboiled before adding to the assay. In lane 5, the reaction includes 133 μg/ml GST-GRIP/Y697A mutant. Error bars represent the standard deviations of two independent experiments. Bottom, typical gel autographic images. (C) Inhibition of EE/RE–TGN transport by GST-GRIP is dose dependent with a half-maximal inhibition at concentration of 25 μg/ml. Top, typical autoradiographs of 35S-sulfated STxB. Bottom shows the correspondent quantification curves. Points with deviation error bars indicate that these experiments were independently repeated twice. Transport in the absence of the recombinant protein is defined as 100%.
present data here suggesting that Golgin-97 is likely candidate for a tethering protein functioning in this pathway.

Golgins are Golgi-localized proteins with extensive coiled-coil structure throughout the entire polypeptide, and they include Golgin-45, Golgin-67, Golgin-84, GM130/Golgin-95, Golgin-160/GCP170, Golgin-245/p230/Im Golgin-1, GCC88, GCC185, p115, Giantin, GMAP-210, and CASP in mammalian cells; and Uso1p (similar to p115), Imh1p, Coy1p (similar to CASP), and Grp1p (similar to Giantin, p115) in yeast (Barr and Short, 2003; Gillingham and Munro, 2003). Most Golgins are autoantigens and were cloned by screening expression libraries with their autoantibodies, such as Golgin-160 (Fritzler et al., 1994), GMAP-210 (Rios et al., 1994), and Golgin-245/p230 (Fritzler et al., 1995), Golgin-97 (Griffith et al., 1997), and Golgin-67 (Eystathioy et al., 2000). Among them, three Golgins, namely, GM130, Giantin, and p115, are the most-well studied. GM130 and p115 form part of the Golgi matrix, which maintains the cisternal stacking architecture of the Golgi apparatus (Nakamura et al., 1995; Seemann et al., 2000). GRASP-65 interacts with GM130 and also functions in the stacking of the Golgi cisternae (Barr et al., 1997). In addition, GM130, p115, and Giantin are tethering molecules. The C-terminal part of p115 can interact with both GM130 and Giantin. p115 is recruited to COPII vesicles by Rab1-GTP (Allan et al., 2000) or on the COPII retrograde vesicles by its interaction with Giantin (Sonnichsen et al., 1998), whereas GM130 is restricted to cis-Golgi membrane (Nakamura et al., 1995). The interaction between p115 and GM130 tethers the incoming COPII vesicles with the cis-Golgi membrane and leads to the docking and subsequent membrane fusion mediated by SNAREs (Shorter et al., 2002). The functions of other Golgins are still unclear, but the presence of extensive coiled-coil regions suggests that they could also adopt long rod structures and may likely serve as tethering molecules or matrix proteins for the cisternal architecture of Golgi apparatus.

There are four mammalian Golgins, Golgin-97, Golgin-245, GCC88, and GCC185, and one yeast Golgin, Imh1p, forming a subgroup characterized by the presence of a conserved GRIP domain at their extreme C termini (Barr, 1999; Kjer-Nielsen et al., 1999a; Munro and Nichols, 1999; Luke et al., 2003). The GRIP domains of these Golgins are necessary and sufficient for their targeting to the TGN (Barr, 1999; Kjer-Nielsen et al., 1999a; Munro and Nichols, 1999). The functions of the GRIP-domain containing Golgins are still unclear except that Imh1p (Sys3p) was suggested to function in vesicular transport between endosomes and the late Golgi in yeast (Tsukada et al., 1999). Recently, we and others showed that GRIP Golgins are effectors of small GTPase Arl1 as active Arl1 can interact with the GRIP domain and recruit these Golgins to the Golgi membrane (Lu and Hong, 2003; Panic et al., 2003b; Setty et al., 2003). Arl1 is a Golgi-localized member of the ARF/Arl family of small GTPases (Low et al., 1996) and is implicated in the regulation of Golgi structure and function (Lu et al., 2001), but its exact cellular function is still obscure. In this study, we tested the role of Golgin-97 and Arl1 in endosome–TGN transport utilizing recombinant STXB, which has artificially incorporated sulfation sites. The results demonstrate that both Arl1 and its effector Golgin-97 are required in EE/RE–TGN transport. The in vivo function of Golgin-97 and Arl1 was similarly established by small interference (siRNA)-mediated knockdown and microinjection approaches. Our results thus represent the first direct evidence for a possible function of Golgin-97 as a tethering molecule on TGN for retrograde traffic from the early and/or recycling endosomes and highlight that the Arl1-GRIP Golgins pathway could be a key regulatory process for endosome–TGN traffic.

**MATERIALS AND METHODS**

**Antibodies and Reagents**

Alexa Fluor 555-conjugated Cholera toxin B fragment (CTxB) and monoclonal antibody (mAb) CDF4 against human Golgin-97 were from Molecular Probes (Eugene, OR). mAb against β-tubulin and control rabbit IgG for transport assay and immunoprecipitation experiments were obtained from Sigma-Aldrich (St. Louis, MO). mAb against STXB, 13C4, was from American Type Culture Collection (Manassas, VA). mAbs against γ-adaptin, GM130 and Golgin-245, were from BD Biosciences (San Jose, CA). Anti-Myc tag polyclonal antibody was from Upstate Biotechnology (Charlottesville, VA). Sheep
Figure 3. Golgin-97 pAb inhibited in vitro EE/RE-TGN transport of STxB. Top, quantification of bottom panels, which are typical autoradiographs of \(^{35}\)S-sulfated STxB. (A) Golgin-97 pAb, but not control rabbit IgG, inhibited STxB transport in a dose-dependent manner. The STxB transport was reduced to 19% with the increasing amount of Golgin-97 pAb added to a concentration of 133 \(\mu\)g/ml (black bars), whereas the transport was still 85% when control rabbit IgG was increased to the same concentration (gray bars). Error bars represent the standard deviations of two independent experiments. Bottom, typical autoradiograph of \(^{35}\)S-sulfated STxB in the presence of increasing amount of Golgin-97 pAb or control rabbit IgG. Lane 1, transport assay in the absence of cytosol, serving as a negative control. The transport assays conducted in lanes 2–5 contained the indicated amount of Golgin-97 pAb or control rabbit IgG. (B) Inhibition of Golgin-97 pAb in STxB transport was specific as it could be relieved by preincubation with antigen. Lane 1, transport reaction in the absence of cytosol serving as a negative control. Lane 2, complete reaction, as positive control and the STxB transport was set as 100%. Lane 3, 33 \(\mu\)g/ml Golgin-97 pAb was added. Lane 4, 33 \(\mu\)g/ml Golgin-97 pAb was first neutralized by 67 \(\mu\)g/ml antigen (Ag, GST-Golgin-97CC) before addition to the assay. In lane 5, 67 \(\mu\)g/ml Ag was added to the reaction. Lane 6 contains 33 \(\mu\)g/ml GST protein. In lane 7, 67 \(\mu\)g/ml GST protein was added to the reaction. Error bars represent the standard deviations of two independent experiments.
Figure 4. The membrane pool of Golgin-97 was responsible for in vitro EE/RE-TGN transport of STxB. (A) HeLa cytosol used in the STxB transport assay were mock depleted by control rabbit IgG (lane 1) or Golgin-97 pAb (lane 2). Top, Golgin-97 levels in two treated cytosols. About 90% of Golgin-97 was depleted in Golgin-97 pAb-treated cytosol. In B–D, top shows the relative percentage of STxB transport in bar charts. A typical set of autoradiographs of 35S-sulfated STxB is shown in the bottom panels for each experiment. Black bars are positive controls for adjacent gray bars and their STxB transports are set as 100%. Error bars represent standard deviations of two independent experiments. (B) Transport of STxB was reduced only slightly using Golgin-97 depleted HeLa cytosol. Lane 1, reaction without cytosol. Lanes 2 and 4, assays with 1 and 2 mg/ml control depleted cytosol, respectively. Lanes 3 and 5, assays with 1 and 2 mg/ml Golgin-97 pAb-depleted cytosol, respectively. (C) Separate treatment of membrane and cytosolic pools of Golgin-97 affected STxB transport differently. Lane 1, reaction without cytosol, as negative control. Lane 2, complete reaction (cytosol and semi-intact cells), as positive control, and the transport is set as 100%. Lane 3, Golgin-97 pAb was mixed with...

Preparation of Recombinant STxB and In Vitro Endosomes to TGN Transport Assay

A plasmid expressing the modified Shiga toxin B fragment, STxB-Sulf2, was generously provided by Dr. Ludger Johannes (Institute Curie, Paris, France) and transformed into *Escherichia coli* and transformed into *E. coli* DH5α as described previously (Lowe et al., 1996). Purified glutathione S-transferase (GST)-Golgin-97C fusion protein (400 μg) was diluted in 1 ml of phosphate-buffered saline (PBS). The protein was stored at -80°C (complete for the first time injection and incomplete for the subsequent booster injections) (Pierce Chemical, Rockford, IL). The emulsified antigen was injected subcutaneously into female New Zealand White rabbit (Sem-bossing Laboratory Animals, Center, Singapore) once per 10 d. Rabbit serum was collected after fifth injection and subsequently after each boost injection.

To purify the antibody, GST or GST-Golgin-97C was cross-linked covalently to glutathione Sepharose 4B beads (Amersham Biosciences UK) by using dimethyl pimelidate (Sigma-Aldrich). Serum was first incubated with GST beads to preabsorb antibody against GST. Then, the unbound serum was subsequently incubated with GST-Golgin-97C cross-linked glutathione Sepharose beads. After extensive washing, the bound Golgin-97 polyclonal antibody was eluted by 50 mM glycine, pH 2.8, dialyzed in PBS, and concentrated.

Golgin-97 Depletion from HeLa Cytosol

Golgin-97 polyclonal antibody (pAb) or control rabbit IgG was immobilized on the Zeise X Protein A Immunoprecipitation beads (2 mg of antibody per 1 ml of equivalent volume of beads) (Pierce Chemical). HeLa cell cytosol (8 mg/ml) was incubated with the immobilized antibody beads (400 μl of cytosol per 200 μl of beads) at 4°C for 1.5 h. The nonbinding fractions representing the Golgin-97 pAb and control IgG-treated cytosols were recovered after spin filtration. The efficiency of the depletion was subsequently examined by Western blot analysis.

Temporal Sensitivity of Golgin-97 and Syntaxin 16 pAbs during In Vitro Transport Assay

Standard transport reactions at 37°C were allowed to proceed for 10, 15, 20, 30, 40, 50, 70, and 90 min, respectively, and stopped by incubation on ice. Either 133 μg/ml anti-Golgin-97 or 20 μg/ml final concentration of anti-syntaxin 16 pAb was added at these time points. The nonbinding fractions representing the Golgin-97 pAb and control IgG-treated cytosols were recovered after spin filtration. The efficiency of the depletion was subsequently examined by Western blot analysis.

Cell Culture, Transfection, Immunofluorescence Microscopy, and Morphology Statistics

The codon region of Golgin-97C was PCR cloned into pDMycc-neo to produce a N-terminal double Myc-tagged fusion protein. Golgin-97 GRIP domain and GRIP/Y967A in pGADT7 (Lu and Hong, 2003) were cut by EcoRI and NotI and ligated to the pEGFP-C2 vector (BD Biosciences, Palo Alto, CA) to express EGFP-GRIP and EGFP-GRIP/Y967A. Arl1-Q71L in pSTAG was described previously (Lu et al., 2001). HeLa cells were cultured in RPMI medium supplemented with 10% fetal bovine serum at 37°C. Transient transfection of Golgin-97C in pEGFP-C2 vector (BD Biosciences, Palo Alto, CA) according to published protocol. Indirect immunofluorescent microscopy was performed as described previously (Lu et al., 2003). Images were taken using Bio-Rad 1024 (Bio-Rad) or Zeiss LSM510 (Carl Zeiss, Jena, Germany) confocal microscopes. In morphology statistical analysis of Figure 6B, ~100 cells highly expressing the following chimera were counted for either perinuclear or peripheral staining of STxB: EGFP-GRIP, EGFP-GRIP/Y967A, and Myc-Golgin-97C. Around 100 nontransfected cells on EGFP-GRIP transfected coverslip were counted as negative controls. For analysis of Figure 9B, those cells with both injection and STxB internalization were examined for STxB distribution from confocal images. About 50 cells were counted from cell microinjected with antibodies against Golgin-97 or control IgG.

Knock Down of Endogenous Arl1 or Golgin-97 by siRNA

Arl1-specific and control siRNA duplexes were the same as described previously (Lu and Hong, 2003). The human Golgin-97-specific duplex siRNA oligonucleotides (siRNA: 5′-AAG UCC UGC AAG AAG-3′ and siRNA: 5′-AAG GUC UGC AAG AAG-3′) were synthesized at Dharmacon Research (Lafayette, CO). HeLa cells were transfected with siRNA by using Oligofectamine transfection reagent (Invitrogen, Carlsbad, CA) according to protocol provided by Dharmacon Research. Cells were processed for immunofluorescence or immunoblotting after 48 h of incubation. In some experiments, siRNA-treated HeLa cells were continuously internalize STxB (at 1 μM final concentration) or CTxB-Alexa Fluor 555 (at 5 μM final concentration) for 3 h before fixation.
**STxB In Vivo Transport Assay by Using siRNA-treated HeLa Cells**

After 48 h of incubation, siRNA-treated HeLa cells were subjected to in vivo STxB transport assay. Cells were first washed twice and then subsequently incubated at 37°C for 1 h with sulfate-free medium (sulfate-free minimal essential medium [Sigma-Aldrich] supplemented with 5% dialyzed fetal bovine serum [Invitrogen]). The cells were then incubated with sulfate-free medium containing 1 μM STxB, 0.5 mM/μl Na2SO4 (Amersham Biosciences UK) for 90 min at 37°C. After washing three times by cold PBS (containing 3 mM Mg2+ and 1 mM Ca2+), the cells were solubilized by 2× SDS sample buffer and the sulfated STxB was resolved by 15% SDS-PAGE followed by visualization via autoradiography. The levels of endogenous Arl1, Golgin-97, and β-tubulin were assessed by Western blotting.

**Microinjection of Golgin-97 pAb into HeLa Cells**

Golgin-97 pAb and preimmune IgG were dialyzed in PBS and concentrated to ∼8 mg/ml. HeLa cells grown on the coverslips were microinjected with the antibody by using Eppendorf microinjection system (Hamburg, Germany). Injected HeLa cells were incubated in normal culture medium at 37°C for 180 min before fixation and immunofluorescent labeling. For CTxB morphological transport assay, injected cells were first incubated in normal condition for 50 min before the addition of 5 μg/ml Alexa Fluor 555-conjugated CTxB and subsequent internalization for 30 min. After washing away noninternalized CTxB, cells were incubated in normal condition and the internalized CTxB was chased for 60 min before immunofluorescent labeling.

**RESULTS**

**Recombinant GRIP Domain of Golgin-97 Inhibited In Vitro Transport of STxB from the EE/RE to TGN**

Due to its TGN localization and general structural similarity to other Golgins implicated in tethering processes, Golgin-97 was subsequently tested in the STxB transport assay by using an established system measuring the transport of STxB (Mallard et al., 2002). The GRIP domain of Golgin-97 is essential and sufficient for its interaction with Arl1-GTP (Lu and Hong, 2003; Panic et al., 2003; Panic et al., 2003b; Setty et al., 2003) and subsequent targeting to the Golgi apparatus. Arising from the importance of the GRIP domain, recombinant Golgin-97 GRIP domain GST fusion protein (GST-GRIP; Figure 1A) was first tested in the STxB transport assay. Briefly, sulfate-starved HeLa cells were incubated with STxB at 18°C to continuously accumulate STxB at EE/RE before the plasma membrane of cells was selectively perforated by streptolysin O. The resulting semimembrane cells were then incubated at 37°C for 90 min with the transport mix containing: HeLa cytosol, ATP regenerating system, 35S-sulfate, and recombinant GST-GRIP or control proteins. The arrival of recombinant STxB at the TGN was monitored by a TGN-specific GRIP or control proteins. The arrival of recombinant STxB at the TGN was reduced to 30% as shown in lane 2 of Figure 1B. The transport was restored to almost complete level (96%) (lane 3) when the same amount of GST-GRIP was heat-denatured before addition, suggesting that the inhibition requires the intact conformation of the GRIP domain. When the conserved residue Y697, which is essential for interaction with Arl1 and for Golgi targeting (Barr, 1999; Kjer-Nielsen et al., 1999a; Munro and Nichols, 1999; Lu and Hong, 2003; Panic et al., 2003b), was mutated to Ala, the resultant fusion protein, GST-GRIP/Y697A (lane 5), exhibited little inhibition toward STxB transport relative to the control (lane 4). Furthermore, with increasing amounts of GRIP-GRIP added to the assay, the transport of STxB was correspondingly reduced to a plateau of ∼20% (Figure 1C), indicating that the inhibition is dose dependent. The half-maximal inhibition was achieved at a concentration of 25 μg/ml GST-GRIP. In contrast, with increasing amount of GST-GRIP/Y697A introduced, the transport of STxB was essentially not affected, implying that a functional GRIP is required for the inhibition.

The dose-dependent inhibition by the GRIP domain probably arises from the competitive replacement of endogenous GRIP Golgins interacting with a limited amount of cellular binding partners. One likely candidate is active Arl1, which has been found to interact with and recruit GRIP domain Golgins to the membrane (Lu and Hong, 2003; Panic et al., 2003b; Setty et al., 2003). Large amount of GST-GRIP may displace endogenous GRIP Golgins from the Golgi membrane. The loss of its inhibitory property by Y697A mutation in GRIP, which disrupts Arl1 and GRIP interaction (Lu and Hong, 2003; Panic et al., 2003b), is supportive to this interpretation. These results imply that Golgin-97 and/or other GRIP domain Golgins could participate in EE/RE–TGN transport.

**Polyclonal Antibody against Golgin-97 Inhibited In Vitro EE/RE–TGN Transport**

We raised rabbit polyclonal antibodies against human Golgin-97 by using part of its central coiled-coil region (Golgin-97CC; Figure 1A). The purified Golgin-97 polyclonal antibody (Golgin-97 pAb) detected a single endogenous protein of ∼97 kDa in HeLa but not in normal rat kidney (NRK) cell lysate (lane 1 and 2, respectively; Figure 2A), showing that the pAb is specific to human Golgin-97. From 293T cell lysate, this pAb, but not the control rabbit IgG, efficiently immunoprecipitated an endogenous protein of ∼97 kDa, which was detected by immunoblotting with a commercial Golgin-97 mAb (Figure 2B). Furthermore, indirect immunofluorescent staining of HeLa cells with the pAb gave a perinuclear signal, which was colocalized with labeling by the mAb against Golgin-97 or Golgin-245 (unpublished data). These experiments thus demonstrated that the generated pAb specifically recognizes endogenous human Golgin-97 and does not cross react with other human Golgins or Golgin-97 in other species.

The Golgin-97 pAb was then applied to the in vitro EE/RE–TGN transport assay and found to inhibit STxB transport in a dose-dependent manner relative to controls, in which the same amount of nonspecific rabbit IgG was used (Figure 3A). With a final concentration of 133 μg/ml Golgin-97 pAb in the assay, STxB transport was reduced to 19%. This degree of inhibition is similar to that exhibited by GST-GRIP, because both have a half-maximal inhibitory concentration at around 25 μg/ml. Considering the antibody has a much larger molecular weight, the pAb is probably a more potent inhibitor.

The specificity of inhibition by Golgin-97 pAb was revealed by antigen neutralization experiments as shown in Figure 3B. The 60% inhibition of the STxB transport by 33 μg/ml Golgin-97 pAb (Figure 3B, lane 3) could be relieved by preincubation of pAb with a noninhibitory amount (lane 5) of its antigen GST-Golgin-97CC (lane 4). This inhibition was not neutralized by preincubation with just GST protein (lane 6). Furthermore, the Fab fragment of Golgi-97 also exhibited inhibition in the transport assay (unpublished data). Together, these experiments corroborate and further support the above findings and suggest that Golgin-97 is important in EE/RE–TGN transport.
The Membrane Pool of Golgin-97 Is Responsible for In Vitro EE/RE–TGN Transport

As a peripheral Golgi membrane protein, Golgin-97 has both cytosolic and membrane-associated pools. In HeLa cells, >80% of Golgin-97 is in the cytosol as assessed by subcellular fractionation (unpublished data). When the HeLa cytosol used in the STxB transport assay was incubated with Golgin-97 pAb and protein A-Sepharose, ~90% of Golgin-97 was depleted (Figure 4A, lane 2) compared with the mock-depleted cytosol by using control rabbit IgG (Figure 4A, lane 1). Both Golgin-97–depleted and mock-depleted cytosols were tested for STxB transport in vitro (Figure 4B). It was found that transport events observed with Golgin-97–depleted cytosol were only slightly reduced (~80–90%, lanes 3 and 5) compared with levels with equal amounts of mock-depleted cytosol (defined as 100%, lanes 2 and 4). This reduction was marginal with the inhibitory effects of GST-GRP and Golgin-97 pAb on the transport. This prompted us to examine the in vivo effect of reducing Golgin-97 level. When Golgin-97 was reduced by 70% by using the siRNA knock-down approach (Figure 7A), in vivo transport of STxB to the TGN was reduced to 69% (Figure 7B), suggesting an essential role of Golgin-97 in vivo.

The exchange of Golgin-97 between the membrane and cytosolic pools could be so slow that the equilibrium and thus the reduction of Golgin-97 in membrane pool would be achieved only in long time (days) siRNA treatment, but not in short time (hours) incubation during in vitro transport assay. The limited transport effect obtained from Golgin-97–depleted cytosol could be explained by the possibility that the membrane-bound Golgin-97, but not its cytosolic pool, is the active participant in the in vitro EE/RE–TGN transport. This possibility seems likely as only the membrane pool of another Golgin, p115, is responsible for in vitro ER–Golgi transport and cytosol depletion of p115 only results in partial inhibition of transport (Allan et al., 2000).

To examine this possibility, we treated the cytosol and/or semiintact cells separately with the antibody against Golgin-97 and allowed the transport to finish in three steps. In step 1, either semiintact cells (Figure 4C, lanes 6 and 7) or HeLa cell cytosol (lanes 4 and 5), or both (lanes 2 and 3) were incubated with (lanes 3, 5, and 7) or without (lanes 2, 4, and 6) Golgin-97 pAb on ice for 1 h (step 1). In step 2, the excess amount of Golgin-97 pAb was neutralized with double amount of antigen (lanes 4–7) before the assay was completed with the supplementation of semiintact cells (lanes 4 and 5) or HeLa cytosol (lanes 6 and 7) (step 3). The transport of STxB in control assays was set as 100% (lanes 2, 4, and 6). When the cytosol alone was treated by antibody, there was little inhibition of STxB transport (compare lanes 5 and 4). In contrast, when the semiintact cells alone were treated with Golgin-97 pAb, the transport of STxB was reduced to ~50% (compare lanes 7 and 6), similar to the 40% inhibition obtained when both semiintact cells and cytosol were treated (compare lanes 3–2). Unlike antibody neutralization experiment in Figure 3B, the antigen addition described (Figure 4C, lane 7) did not neutralize the inhibition of this antibody in EE/RE–TGN transport. In lane 4 of Figure 3B, the antibody was first incubated with twice amount of antigen before its contact with semiintact cells. The antigen-occupied antibody would not interact with membrane-bound Golgin-97. However, in lane 7 of Figure 4C, the antibody was first allowed to bind membrane Golgin-97. The excess free antibody was subsequently neutralized by the antigen. We think that once bound to membrane Golgin-97, the antibody could not be displaced by its recombinant antigen under our experimental condition.

Because our Golgin-97 pAb reacts only with human Golgin-97 but not its homolog from rat, we have reconstituted in vitro transport assay by using rat liver cytosol in the presence of Golgin-97 pAb. Under such a setting, human Golgin-97 associated with semiintact HeLa cells (but not cytosolic rat Golgin-97) was recognized by the antibody. Transport of STxB under this condition was reduced to 30% by Golgin-97 pAb (Figure 4D, lane 3), suggesting that the majority of cytosolic rat Golgin-97 could not rescue the...
Figure 6. Overexpression of EGFP-GRIP domain prevented the perinuclear accumulation of STxB in HeLa cells. (A) HeLa cells were transiently transfected to overexpress EGFP-GRIP (a–c), EGFP-GRIP/Y697A (d–f), or Myc-Golgin-97CC (g–i). Cells were subsequently allowed to continuously internalize STxB for 3 h and processed to reveal STxB by IF (b, e, and h). Bars, 10 μm. (B) Statistical analysis of the morphology relating the ratio of cells with perinuclear to cells with only peripheral distribution of STxB under different transfection conditions. The ratio in nontransfected cells is defined as 100%. In each case, ~100 cells, which contain both the exogenously over expressed protein and internalized STxB, were randomly chosen for scoring the distribution of STxB.
Golgin-97 is Required before the SNARE-mediated Docking/Fusion Step

Syntaxin 16 is a key component of a SNARE complex involved in EE/RE-TGN transport (Mallard et al., 2002). We have examined the kinetics of inhibition exhibited by anti-Golgin-97 in relation to anti-Syntaxin 16 pAb to resolve the temporal requirement of these two molecules during EE/RE-TGN transport (Figure 5). The complete in vitro transport cocktail was assembled and the transport was allowed to proceed as per normal. The Golgin-97 pAb (Figure 5A, top) or Syntaxin 16 pAb (Figure 5A, bottom) was added at various time points, and the transport reactions were resumed for a total time of 90 min. Sulfation of STxB at the TGN for each assay is shown in Figure 5A, and the relative inhibition is quantified in Figure 5B. The 90-min lane in Figure 5A shows the complete reaction without the addition of antibodies and the inhibition was set as 0% and the 10 min lane was set as 100% inhibition for each time point (Figure 5B). At early time points (<30 min), the transport of STxB was sensitive to both Golgin-97 and Syntaxin 16 pAbs. However, the inhibition by Golgin-97 pAb quickly declined when the prereaction time increased. After 40 min of prereaction, STxB trafficking to TGN became almost insensitive to Golgin-97 pAb as the relative inhibition curve reached its minimum platform; in contrast, the trafficking of STxB was still sensitive to Syntaxin 16 pAb up to the 70-min time point, when inhibition of transport was reduced to the minimum level.

Syntaxin 16 functions as part of the t-SNARE complex together with Syntaxin 6 and Vti1a in EE/RE-TGN transport (Mallard et al., 2002). The finding that Golgin-97 is likely required in a step earlier than Syntaxin 16 implicates Golgin-97 in tethering events. It suggests that one of Golgin-97’s functions is to serve as a tethering molecule, similar to p115, GM130 and Giantin, to mediate long-range “landing” of transport vesicles and tether them to the target membranes to facilitate the subsequent docking and fusion mediated by SNAREs.

Overexpression of EGFP-Golgin-97 GRIP Prevented the Perinuclear TGN Accumulation of STxB in HeLa Cells

To test the in vivo effect of the Golgin-97 GRIP domain on retrograde trafficking of STxB to the TGN, EGFP-Golgin-97 GRIP domain (EGFP-GRIP; Figure 1A) was overexpressed in HeLa cells by transient transfection followed by 3 h of continuous internalization of STxB. When expressed at high level, EGFP-GRIP was mainly cytosolic (Figure 6A, a) instead of Golgi localization, consistent with our understanding that the GRIP domain-mediated Golgi targeting is a saturable process (Kjer-Nielsen et al., 1999a,b; Yoshino et al., 2003). In these cells, internalization of STxB was still observed, but the distribution of internalized STxB was peripheral (h), instead of perinuclear TGN as seen in the control (h). When the conserved residue Y697 of Golgin-97 GRIP domain was mutated to Ala, the inhibition of STxB transport to the Golgi apparatus was not observed and internalized STxB was localized to the perinuclear TGN, in line with our in vitro result that the inhibition requires a functional GRIP domain. As a negative control, over expression of Myc tagged Golgin-97 central coiled-coil region (Golgin-97CC; Figure 1A), which is cytosol distributed regardless of expression levels (Figure 6A, g), did not prevent the perinuclear accumulation of internalized STxB (h). The peripheral spotty localization of STxB in b is suggestive of endosomes, a potential site where the STxB transport is arrested. Statistical

Figure 7. Knockdown of Arl1 or Golgin-97 inhibited in vivo trafficking of STxB to the TGN. (A) HeLa cells were transfected with indicated siRNAs. After 48 h, the total cell lysate was subjected to immunoblotting analysis to detect Golgin-97 (lanes 1 and 2 in the top panel), Arl1 (lanes 3 and 4 of the top panel), and β-tubulin (bottom). (B) The relative transport of STxB to Golgi in siRNA-treated HeLa cells. siRNA-treated HeLa cells were allowed to internalize STxB for 90 min in the presence of [35S]-sulfate. The [35S]-sulfated STxB was revealed by autoradiograph (middle panel shows a typical result). The loading of each lane was normalized by immunoblotting with antibody against β-tubulin (bottom). For each lane, the relative ratio of sulfated STxB to β-tubulin densities was quantified as bar chart in the top panel. Error bars represent standard deviations of four independent experiments. Knock down of Golgin-97 or Arl1 significantly reduced the sulfation of STxB compared with controls (p < 7E-5 and 0.006, respectively).
analysis of the ratio of transfected cells with perinuclear to peripheral STxB in each case is shown in Figure 6B.

**Knock Down of Arl1 or Golgin-97 Inhibited In Vivo Trafficking of STxB to TGN**

Our previous study showed that Arl1-GTP interacts with the GRIP domain and this interaction regulates the Golgi recruitment of Golgin-97 (Lu and Hong, 2003). Because Golgin-97 is important for EE/RE–TGN transport, Arl1 also might function in this pathway. Polyclonal antibody against rat Arl1 did not show any inhibition in our EE/RE–TGN in vitro transport assay (unpublished data), probably because the epitopes are located at nonessential region of Arl1 (Lu and Hong, 2003). We have thus devel-

---

**Figure 8.** Microinjection Golgin-97 pAb-fragmented Golgi apparatus. HeLa cells were microinjected with Golgin-97 pAb (A–D and I–K) or preimmune rabbit IgG (E–H and L–N) and subsequently triple labeled to reveal Golgin-245 (A and E), TGN46 (B and F) and injected rabbit IgG (C and G) or double labeled to reveal γ-adaptin (I and L) and injected rabbit IgG (J and M). In D and H, the intensity of blue color was reduced fivefold for clearer observation of red and green signals. Bars, 10 μm.
opened an in vivo STxB transport assay by using siRNAs to selectively knock down the endogenous level of Arl1 or Golgin-97. In a typical experiment (Figure 7A), endogenous levels of both Golgin-97 (lane 1) or Arl1 (lane 3) were reduced to <30% of controls (lanes 2 and 4) by their respective siRNAs. The knock down of both Arl1 (Figures 10 and 12) and Golgin-97 (unpublished data) did not impair the internalization of STxB in immunofluorescent experiments. Transport of STxB to the TGN was reduced to 66% in Arl1 siRNA-treated (Figure 7B, lane 1) and 69%

Figure 9. The retrograde trafficking of CTxB was arrested before the Golgi when Golgin-97’s functions were interfered by its microinjected pAb. (a) HeLa cells were microinjected with Golgin-97 pAb (A–D) or preimmune rabbit IgG (E–H) and then allowed to internalize Alexa Fluor 555-conjugated CTxB for 30 min and followed by 60-min chase. Cells were subsequently triple labeled to reveal CTxB (A and E), GM130 (B and F), and injected rabbit IgG (C and G). In D and H, the intensity of blue color was reduced fivefold for clearer observation of red and green signals. Bars, 10 μm. (b) For those injected cells, which also internalized CTxB, the distribution of CTxB was analyzed and the percentage of cells with CTxB in the Golgi region was shown in the bar chart. About 50 cells microinjected with Golgin-97 pAb or control rabbit IgG were examined and scored.
in Golgin-97 siRNA1-treated HeLa cells (Figure 7B, lane 2) relative to HeLa cells under control siRNA treatment (Figure 7B, lane 3). A similar result was obtained using another Golgin-97–specific siRNA (Golgin-97 siRNA2; unpublished data). Although the assay measures transport of STxB from the plasma membrane to TGN via endosomes, the results, together with the trans-Golgi localization of both Arl1 and Golgin-97, suggest that both Arl1 and Golgin-97 are involved in the in vivo STxB retrograde transport to TGN.

Interference of Endogenous Golgin-97 Function by Antibody Microinjection Fragmented the Golgi Apparatus and Arrested the EE/RE-to-TGN Transport of CTxB

Our siRNA knock-down approach to reduce endogenous Golgin-97 did not give a morphologically observable phe-

Figure 10. Internalized STxB was arrested at a stage before the Golgi in Arl1 knocked down HeLa cells. Arl1 siRNA (A–C and G–I) and control siRNA (D–F and J–L)-treated HeLa cells were allowed to internalized STxB for 3 h and subsequently double labeled to reveal internalized STxB (A, D, G, and J) and Arl1 (B and E) or GT (H and K). Bars, 10 μm.
notype, such as the change of Golgi organization or STxB retrograde trafficking (unpublished data), probably due to the incomplete knock down of cellular Golgin-97 in our experiments. Residual amount of Golgin-97 could account for maintaining the morphology of Golgi structure and EE/RE-to-TGN trafficking pathway. Although the amount of STxB transported from endosome to TGN is reduced, STxB is still present in the Golgi region in these Golgin-97 knock-down cells.

To explore the in vivo function of Golgin-97 by an independent approach, HeLa cells were microinjected with Golgin-97 pAb to interfere with the function of Golgin-97. When the function of endogenous Golgin-97 was disturbed by its antibody, the morphology of Golgi was changed dramatically compared with correspondent preimmune IgG-injected cells (Figures 8 and 9). First, the Golgi apparatus was fragmented as shown by trans-Golgi/TGN markers Golgin-245 (Figure 8A) and TGN46 (Figure 8B), and cis-Golgi marker GM130 (Figure 9a, B), compared with their compact perinuclear distributions in control cells (Figures 8, E and F, and 9a, F). Especially, in Golgin-97 pAb-injected cells, TGN46 only partially colocalized with Golgin-245. A significant amount of TGN46 was separated from Golgin-245 and showed a peripheral vesicular profile (Figure 8B). The rat homolog of TGN46, TGN38, was reported to cycle from the plasma membrane to the TGN through EE/RE (Mallet and Maxfield, 1999), so the morphological separation of TGN46 from Golgin-245 could be explained by suggesting that the EE/RE-to-TGN transport of TGN46 was inhibited when the normal function of Golgin-97 was disturbed. Accordingly, the vesicular profile could represent arrested TGN46 in EE/RE en route to TGN. Second, the majority of AP-1 (γ-adaptin)-positive staining became a peripherally distributed and diffused vesicular profile (Figure 8I) compared with the control cells, in which AP-1 nicely concentrated to the TGN with some peripheral distribution (Figure 8L). AP-1 clathrin-coated vesicles were reported to be responsible for EE/RE-to-TGN retrograde trafficking (Mallard et al., 1998). The diffuse localization of AP-1 clathrin coat probably is a reflection that these AP-1 clathrin vesicles failed to target or tether to the fragmented TGN when the function of Golgin-97 was interfered by injected antibody.

A commercially available CTxB conjugated with Alexa Fluor 555 was used to study the retrograde trafficking in microinjected cells, because CTxB uses a similar trafficking itinerary as STxB (Sandvig and van Deurs, 2002a,b). The EE/RE-TGN traffic of CTxB also was inhibited in Golgin-97 pAb-injected HeLa cells (Figure 9). In control IgG-injected cells, the internalized CTxB was colocalized with GM130 (Figure 9a, E–H). In the presence of Golgin-97 pAb, the internalized CTxB distributed peripherally and did not colocalize with GM130, whose labeling was fragmented under this condition (Figure 9a, A–D). A morphological statistical analysis indicated that CTxB reached fragmented Golgi marked by GM130 in only 18% internalization positive and Golgin-97 pAb-injected cells, whereas, among control IgG-injected cells, 95% internalization-positive cells had CTxB in the Golgi apparatus (Figure 9b), corroborating Golgin-97 is essential for EE/RE-to-TGN trafficking in vivo.
Internalized StxB Was Arrested at a Stage before Golgi in Arl1 Knocked-Down HeLa Cells

We next investigated the distribution of internalized StxB in Arl1 knocked-down HeLa cells. After siRNA treatment to knock down endogenous Arl1, HeLa cells were allowed to continuously internalize StxB for 3 h. As reported previously (Lu and Hong, 2003), the majority of cells showed only trace amounts of Arl1 that were barely visible through immunofluorescent confocal microscope (Figure 10B). In cells with undetectable levels of Arl1, the internalization of StxB and the morphology of trans-Golgi apparatus, as marked by GT, looked normal (unpublished data). The StxB was localized to perinuclear spotty structures in these Arl1 knocked-down cells (Figure 10A), and it did not overlap with the staining of reduced endogenous Arl1, which was barely detectable (Figure 10C). Instead, the perinuclear StxB was often found to surround the Golgi labeled by the remaining Arl1, indicating that StxB did not reach the Golgi apparatus. On the other hand, in control siRNA-treated cells, the internalized StxB showed extensive colocalization with the endogenous Arl1 (Figure 10, D–F). The failure of StxB to reach Golgi apparatus in Arl1 siRNA-treated cells is also evident in G–I of Figure 10, where StxB did not colocalize with GT, in contrast to a very good colocalization in control siRNA-treated cells (J–L). Different from the knock down of Golgin-97, the knock down of Arl1 could reduce the Golgi association of all its effectors, including GRIP domain Golgins, such as Golgin-97 and Golgin-245 (Lu and Hong, 2003), and other unidentified effectors, thus producing more pronounced morphological effect on StxB transport than knock down of Golgin-97 alone. Unlike the Golgin-97 pAb microinjection experiment, in which the Golgi apparatus was fragmented, the remaining Golgin-97 level in these Arl1 knock-down cells could still be high enough to maintain the integrity of Golgi structure. Corroborating with the knock-down experiments, internalized StxB also failed to reach the Golgi apparatus in cells expressing dominant active Arl1 (Arl1-Q71L) (Figure 11). The results, together, suggest that Arl1 is important for in vivo EE/RE–TGN transport of StxB.

Transport to the TGN of CTxB also was examined in the Arl1 knocked-down cells. In contrast to the control siRNA-treated cells (Figure 12, E–H), in which Arl1 (E), GM130 (F) and CTxB-Alexa Fluor 555 (G) colocalized very well. However, internalized CTxB (C) in Arl1 knocked-down cell (A) did not colocalize with GM130 (B), suggesting that Arl1 could be important for general traffic from the EE/RE to the TGN in vivo.

DISCUSSION

In this study, we provide biochemical and cell biological evidence that Arl1 and its effector Golgin-97 play a role in EE/RE–TGN transport. To our knowledge, our report presents the first direct evidence that supports a role of a specific GRIP Golgin (Golgin-97) in a defined intracellular transport event. Golgin-97 may likely represent the first tethering molecule revealed to participate in EE/RE–TGN transport in mammalian cells. Several lines of evidences support these conclusions. The first arises from our demonstration that the recombinant GST-Golgin-97 GRIP domain (GST-GRIP) but not its Y697A mutant (GST-GRIP/Y697A), is a potent inhibitor in the in vitro EE/RE–TGN transport assay. Consistent with this observation, overexpression of EGFP-GRIP but not its Y697A mutant in HeLa cells prevents the trafficking of StxB from the peripheral to the perinuclear Golgi region, implying that StxB does not reach the Golgi apparatus in cells overexpressing EGFP-GRIP. This observation can be explained in that excess amounts of GRIP domain in cells could compete with endogenous GRIP Golgins for limited amounts of common membrane receptor(s), effectively abolishing the membrane association of all GRIP Golgins (Kjer-Nielsen et al., 1999a,b). At the same time, the excess GRIP domain probably displaces membrane-bound Golgin-97, reducing the membrane pool of Golgin-97 and/or other GRIP domain proteins. These results suggest that Golgin-97 and/or other GRIP domain proteins are involved in EE/RE–TGN transport.

Figure 12. Internalized CTxB was similarly arrested at a stage before the Golgi in Arl1 knocked-down HeLa cells. Arl1 siRNA (A–D) and control siRNA (E–H)-treated HeLa cells were allowed to internalize Alexa Fluor 555-conjugated CTxB for 3 h and subsequently triple labeled to reveal Arl1 (A and E), GM130 (B and F) and internalized CTxB (C and G). Bars, 10 μm.
The second line of evidence is based on our study to establish a specific and direct role for Golgin-97 in this retrograde trafficking pathway. We made a specific pAb against human Golgin-97. The antibody is a potent and specific inhibitor in EE/RE–TGN transport of STxB. Because the inhibition exhibited by the antibody can be neutralized by noninhibitory amounts of the antigen, the inhibition must thus be mediated by a specific interaction of the antibody with Golgin-97 in the in vitro transport assay.

Importantly, a role of Golgin-97 in vivo also was revealed. Effective reduction of cellular levels of Golgin-97 by its siRNA significantly reduces the sulfation of STxB, a reaction characteristic of the TGN compartment (Niehr and Huttner, 1990). When functions of endogenous Golgin-97 were disturbed by microinjected Golgin-97 pAb, the Golgi apparatus was fragmented as assessed by cis- and trans-Golgi markers, thus implying that Golgin-97 is essential for the integrity of Golgi structure. The retrograde trafficking of CTxB to the fragmented Golgi also is disrupted in these microinjected cells. Additional support comes from our observation that small GTPase Arl1, which regulates Golgi recruitment of GRIP Golgins, also plays a role in EE/RE–TGN transport in vivo. Selective knock down of endogenous Arl1 prevents STxB trafficking to TGN. First, the knock down of Arl1 reduces the sulfation of STxB in the entire cell population, providing biochemical evidence. Second, in cells with undetectable/reduced Arl1 levels, the internalized STxB is distributed in spotty structures and fails to reach the Golgi apparatus, because it does not colocalize with GT or GM130. Furthermore, transport of another toxin, CTxB, to the Golgi apparatus is arrested at endosome-like structures. Together, these results suggest that Arl1 and Golgin-97 are essential for EE/RE–TGN traffic.

The involvement of Arl1 in endosome to TGN retrograde trafficking is consistent with studies on the yeast Arl1 homolog Arl1p. Deletion of Arl1p results in missorting of carboxypeptidase Y (CPY), probably due to the impaired retrograde trafficking of the CPY receptor Vps10p to the late Golgi (Bonangelino et al., 2002). Arl1p is also reported to genetically or biochemically interact with component(s) of protein machineries that function in endosome–late Golgi trafficking pathway, such as the RIC1p/Rgp1p complex, Ypt6p, and the GARP/VFT/Vps51/52/53/54 complex (Bensen et al., 2001; Panic et al., 2003b). The function of Arl1 seems to be conserved from the yeast to the mammal.

Our data suggest that Golgin-97 is involved in EE/RE–TGN retrograde transport, but its exact function in this process is still obscure. According to several roles recently proposed for Golgins (Gillingham and Munro, 2003), Golgin-97 could be matrix protein for the integrity of trans-Golgi/TGN. Supporting that role, upon interference of its endogenous function by microinjection of Golgin-97 pAb, the trans-Golgi/TGN is fragmented. The fragmentation of cis-Golgi further implies that Golgin-97 might have a global structural role on the Golgi apparatus. Golgin-97 could be a scaffold protein for assembling fusion machinery at the trans-Golgi/TGN membrane. Most importantly, Golgin-97 also could be tethering molecule in this event. It could tether incoming vesicles derived from endosomes-to-Golgi membrane for heterotypic fusion with the TGN. The demonstration that the membrane-bound Golgin-97, but not its cytosolic pool, is directly required for EE/RE–TGN transport suggests that Golgin-97 functions on the membrane. In addition, Golgin-97 is required at a step earlier than Syntaxin 16, implying that Golgin-97 functions before the action of SNAREs. This temporal requirement and its spatial requirement at the membrane present Golgin-97 as a possible tethering molecule. Imh1p (Sys3p), the sole GRIP Golgin in Saccharomyces cerevisiae, is suggested to function before the fusion step in endosome to late Golgi retrograde trafficking (Tsukada et al., 1999), supporting a role of GRIP Golgins as tethering molecules. From these observations, in conjunction with its structural similarities (extensive coiled-coil regions) to other tethering molecules such as GM130, Giantin, p115 and EEA1, we propose that Golgin-97 acts as a tethering molecule for EE/RE–TGN transport and Arl1 regulates the membrane recruitment of this tethering protein as well as other GRIP Golgins.

We and others recently demonstrated that GRIP Golgins form homodimers through both their GRIP and coiled-coil regions (Panic et al., 2003a; Wu et al., 2004). Similar to p115, GM130 and Giantin, the homodimer of Golgin-97 probably adopt a long rod structure, with its C-terminal GRIP domain anchoring to the TGN membrane through interaction with two Arl1-GTP, whereas its N-terminal globular regions extend to the cytosol to mediate the tethering of retrograde transport vesicles derived from endosomes. The tethering function of GRIP Golgins is likely regulated by Arl1. The exchange of GTP for GDP on Arl1 mediated by its cognate yet to be identified GEF initiates the targeting of GRIP Golgins to the TGN membrane. Then, the N-terminal region of GRIP Golgins likely tethers the incoming vesicles by interacting with molecule(s) on the surface of the vesicles. For the tethered vesicles to proceed to the docking/fusion step, a process that is mediated by proteins very proximal to the surface of the TGN membrane (Pfeffer, 1999), the long arm of Golgins is probably a great hindrance and thus it would be necessary to disassemble the Golgins (Barr and Short, 2003). The unique arrangement of the Arl1-GRIP Golgin complex provides a solution to this through sequential hydrolysis of GTPs in two Arl1 molecules in the Arl1/GRIP complex by the unsynchronized action of its GAP(s). The hydrolysis of GTP in either one of two Arl1 molecules, which anchor the Golgin dimer, would abolish the perpendic-ular angle of Golgin dimer to membrane. The Golgin dimer would then collapse, and thus deliver the tethered vesicle into proximity of the membrane. The v-SNAREs on the vesicle, including VAMP3 and VAMP4, then interact with the t-SNARE complex syntaxin 6/syntaxin 16/Vti1a (Mallard et al., 2002) for short-range docking and fusion. At the same time, hydrolysis of GTP in the last Arl1 molecule by its GAP would finally disassemble the membrane anchoring of the Golgin dimer, leaving the vesicle free for fusion.

Our demonstration that Golgin-97 probably functions as a tethering molecule also indicates that other GRIP domain proteins such as Golgin-245, GCC88, and GCC185 are likely to be involved in tethering process of incoming traffic to the TGN. This working model is consistent with the results presented here as well as published studies. Our preliminary characterizations indicate that Golgin-97, Golgin-245, GCC88, and GCC185 do not interact with one another to form heterologimeric complexes (unpublished data), suggesting that these four Golgins may participate in distinct incoming traffic or distinct events of a similar traffic. Further studies along these lines will provide greater understanding of the underlying mechanism at the interface between the endocytic pathway and the biosynthetic pathway at the TGN.

ACKNOWLEDGMENTS

We thank Drs. Tang Bor Luen and Singh Paramjeet for critical reading of this manuscript. This work was supported by a grant from Agency for Science, Technology, and Research (A*STAR, Singapore) to W.H.; W.H. is also a faculty member of the Department of Biochemistry, National University of Singapore.
REFERENCES


